|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | The University of Texas Health Science Center at San Antonio |
|---|---|
| Collaborator: |
American Association of Endodontists |
| Information provided by: | The University of Texas Health Science Center at San Antonio |
| ClinicalTrials.gov Identifier: | NCT00881907 |
Purpose
The purpose of the investigators study is to characterize the composition of the hard and soft tissues present in root canals of teeth previously diagnosed with necrotic pulps and incomplete root formation and treated with a triple antibiotic regeneration protocol. The investigators hypothesis is that treatment of teeth with necrotic pulps and immature apices with triple antibiotic paste will stimulate continued root formation by the deposition of dentin at the root apices. The primary outcome measure will be histological identification of mineralized tissue and adherent cells in the apical third of these teeth.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulp Necrosis |
Drug: Triple Antibiotic Paste |
Phase 0 |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Single Blind (Subject), Parallel Assignment, Pharmacodynamics Study |
| Official Title: | Tissue Characterization in Teeth Treated With a Regeneration Protocol |
| Estimated Enrollment: | 21 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Group A: Experimental
Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
|
Drug: Triple Antibiotic Paste
ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
|
|
Group B: Experimental
Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
|
Drug: Triple Antibiotic Paste
ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
|
|
Group C: Experimental
Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
|
Drug: Triple Antibiotic Paste
ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
|
'Regeneration' as referred to in this protocol refers to the stimulation of continued root formation by the deposition of apical tissues subsequent to disinfection of a necrotic root canal and its contents and creation of a scaffold upon which cells can proliferate. While the proposed treatment protocol is currently being used in clinical practice and has been shown to be successful in case reports and case series, the nature of the proliferating apical tissues remains unknown. Thus, this study is uniquely positioned to address a critical gap in knowledge in the regeneration of a functional pulp-dentin complex. Moreover, results obtained from pediatric cases may well provide the essential foundation of knowledge for endodontists to apply this knowledge to the more difficult situation of regenerating the pulp-dentin complex of the full mature permanent tooth.
Eligibility| Ages Eligible for Study: | 10 Years to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patient Inclusion Criteria:
Tooth inclusion criteria:
Exclusion Criteria:
Patient Exclusion Criteria:
Tooth Exclusion Criteria:
Contacts and Locations| Contact: Erin Locke, RN | 210-567-0895 | locke@uthscsa.edu |
| United States, Texas | |
| University of Texas Health Science Center | |
| San Antonio, Texas, United States, 78229 | |
| Principal Investigator: | Kenneth M Hargreaves, DDS,PhD | University of Texas |
More Information
| Responsible Party: | The University of Texas Health Science Center at San Antonio ( Kenneth M. Hargreaves, DDS, PhD ) |
| Study ID Numbers: | HSC20090152H |
| Study First Received: | April 14, 2009 |
| Last Updated: | April 14, 2009 |
| ClinicalTrials.gov Identifier: | NCT00881907 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Regeneration (revascularization) of dental pulp Immature (Not Completely Developed) Permanent Tooth With a Diagnosis of Pulpal Necrosis |
|
Tooth Diseases Anti-Infective Agents Dental Pulp Necrosis Molecular Mechanisms of Pharmacological Action Polymyxin B Enzyme Inhibitors Bacitracin Pharmacologic Actions Protein Synthesis Inhibitors |
Anti-Infective Agents, Local Anti-Bacterial Agents Necrosis Pathologic Processes Dental Pulp Diseases Therapeutic Uses Stomatognathic Diseases Neomycin |